A recent real-world study confirms that brexucabtagene autoleucel (brexu-cel) is safe and effective for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), matching results from the pivotal ZUMA-3 trial. The study looked at 292 patients treated between 2021 and 2024 and found similar or slightly lower rates of serious side effects compared to the clinical trial. Severe neurotoxicity (ICANS) occurred in 28.8% of patients, and severe cytokine release syndrome (CRS) in 9.8%, lower than trial rates. Most patients required medications like tocilizumab or corticosteroids, which did not reduce the therapy’s effectiveness.
The study also noted that patients with higher disease burden in the bone marrow tended to have higher risks of severe ICANS and CRS. Brexu-cel remained highly effective, with complete remission rates around 71%, consistent with prior trial data.
These findings show that brexu-cel continues to be a strong treatment option but requires careful monitoring for neurologic and inflammatory side effects. Researchers also highlighted obecabtagene autoleucel (obe-cel) as a promising alternative, potentially offering similar outcomes with fewer toxicities, giving doctors more flexibility in tailoring therapy to individual patients.